Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Lymphoma 34Leukemia 34Lymphoma, Follicular 27Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 20Multiple Myeloma 18Breast Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Prostatic Neoplasms 15Lymphoma, Mantle-Cell 15Lymphoma, Large-Cell, Immunoblastic 15Neuroblastoma 14Neoplasms, Plasma Cell 13Myelodysplastic Syndromes 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Hodgkin Disease 13Burkitt Lymphoma 13Leukemia, Myeloid, Chronic-Phase 12Neoplasm Metastasis 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 10Glioblastoma 9Carcinoma, Non-Small-Cell Lung 9Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Ovarian Neoplasms 7Gliosarcoma 7

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × sargramostim × Clear all
NCT05455658 2026-05-05

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

University of Washington

Phase 2 Active not recruiting
33 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Academic and Community Cancer Research United

Phase 2 Active not recruiting
280 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡